43. Study on the effect of picositol on the experimental model of polycystic ovary syndrome

Tran Thanh Tung, Pham Chi Phuong, Dang Thi Thu Hien

Main Article Content

Abstract

The study was conducted to evaluate the effects of Picositol on Wistar rats induced with polycystic ovary syndrome (PCOS) by letrozole. PCOS was induced in female Wistar rats by oral administration of letrozole at 1 mg/kg/day for 21 consecutive days. After the induction phase, the rats were randomly assigned to treatment groups including: control group, positive control group 1 (metformin), positive control group 2 (clomiphene), and two groups receiving Picositol at 0.12 sachet/kg/day and 0.24 sachet/kg/day, respectively. All treatments were administered orally for 15 consecutive days. Throughout the experiment, daily vaginal smear tests were performed to monitor estrous cycle phases. The following parameters were assessed: body weight, serum lipid profile, blood glucose levels, and ovarian histopathological evaluation. The results demonstrated that Picositol, at both doses, significantly reduced serum lipid levels meanwhile the higher dose increased HDL-C level. Additionally, Picositol reduced blood glucose levels and improved ovarian histopathology comparably to the positive control drugs. These findings suggest that Picositol has therapeutic potential in the management of polycystic ovary syndrome (PCOS) in the animal experimental model.

Article Details

References

1. Editor R. International evidence-based guideline for the assessment and management of polycystic ovary syndrome - 2023. Reproductive endocrinology. 2023; (69): 59-79. doi:10.18370/2309-4117.2023.69.59-79.
2. Azziz R. Polycystic Ovary Syndrome. Obstet Gynecol. 2018; 132(2): 321-336. doi:10.1097/AOG.0000000000002698.
3. Dong J, Rees DA. Polycystic ovary syndrome: pathophysiology and therapeutic opportunities. BMJ Med. 2023; 2(1): e000548. doi:10.1136/bmjmed-2023-000548.
4. Teede HJ, Tay CT, Laven JJE, et al. Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2023; 108(10): 2447-2469. doi:10.1210/clinem/dgad463.
5. Ikram-u-Allah, Sabeen N, Iqbal QJ, Zulfiqar S, Wasim T. Myoinositol In Restoring Spontaneous Ovarian Activity in Patients with Polycystic Ovarian Syndrome (PCOS). Esculapio Journal of SIMS. 2023; 16(3): 41-45. doi:10.51273/esc20.251639.
6. Carrasco-Cabezas M, Assmann TS, Martínez P, et al. Folate and Vitamin B12 Levels in Chilean Women with PCOS and Their Association with Metabolic Outcomes. Nutrients. 2024; 16(12): 1937. doi:10.3390/nu16121937.
7. Miao CY, Fang XJ, Chen Y, Zhang Q. Effect of vitamin D supplementation on polycystic ovary syndrome: A meta‑analysis. Experimental and Therapeutic Medicine. 2020; 19(4): 2641-2649. doi:10.3892/etm.2020.8525.
8. Kafali H, Iriadam M, Ozardalı I, Demir N. Letrozole-induced polycystic ovaries in the rat: a new model for cystic ovarian disease. Archives of Medical Research. 2004; 35(2): 103-108. doi:10.1016/j.arcmed.2003.10.005.
9. Hamza AH, AlBishri WM, Alfaris MH. Effect of Vitex agnus-castus plant extract on polycystic ovary syndrome complications in experimental rat model. Asian Pacific Journal of Reproduction. 2019; 8(2): 63. doi:10.4103/2305-0500.254647.
10. Reddy PS, Begum N, Mutha S, Bakshi V. Beneficial effect of Curcumin in Letrozole induced polycystic ovary syndrome. Asian Pacific Journal of Reproduction. 2016; 5(2): 116-122.
11. Rajan RK, M. SSK, Balaji B. Soy isoflavones exert beneficial effects on letrozole-induced rat polycystic ovary syndrome (PCOS) model through anti-androgenic mechanism. Pharmaceutical Biology. 2017; 55(1): 242-251. doi:10.1080/13880209.2016.1258425.
12. Kafali H, Iriadam M, Ozardalı I, Demir N. Letrozole-induced polycystic ovaries in the rat: a new model for cystic ovarian disease. Archives of Medical Research. 2004; 35(2): 103-108. doi:10.1016/j.arcmed.2003.10.005.
13. Unfer V, Carlomagno G, Dante G, Facchinetti F. Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials. Gynecol Endocrinol. 2012; 28(7): 509-515. doi:10.3109/09513590.2011.650660.